Contributions of side effects to contraceptive discontinuation and method switch among Kenyan women: a prospective cohort study

Abstract Background Postoperative nausea and vomiting (PONV) is a common post- operative unpleasant experience and also common following thyroidectomy that may cause for hematoma and post-operative airway obstruction. Several agents have been tried to reduce severity and incidence PONV.This study intended to compare effectiveness of Metoclopramide alone and its combination with Dexamethasone for prevention of PONV after thyroidectomy at Menelik II Hospital.Methods Prospective cohort study was conducted on 76 American Society of Anesthesiologist (ASA) class I and II, adult patients undergone thyroidectomy. A systematic random sampling was applied to identify sample population through skip interval till required sample size was achieved. Study participants were grouped as Group = M (Metoclopramide alone) and Group = MD (Metoclopramide plus Dexamethasone).Following study participant received either 10 mg Metoclopramide or 5mg Metoclopramide plus 4mg Dexamethasone, PONV was recorded at 6, 12 and 24 hours post operatively. Continuous variables were expressed as mean ± SD or median-IQR as appropriate. Analysis was done by independent two sample t test, Manny Whitney U test and χ2 or fisher exact test. P-Value <0.05 was considered as statistically significant.Results The overall incidence of PONV with in the first 24 hours was significantly higher in Group M as compared to Group MD, 24(63.15%) versus 9 (23.68%) respectively with a P-value of < .01. Although difference was insignificant, severity of nausea at 6th, 12th and 24th was still higher in Group M. From side effects, Sedation was significantly lower in Group MD 6 (15.79%) versus 15 (39.47%) with a P-value of <.05. Despite difference was insignificant headache was found higher in Group M 10 (26.31) vs. 6 (10.52) respectively.Conclusions 5mg Metoclopramide combined with 4mg Dexamethasone has significant effects for prophylaxis of post-operative nausea and vomiting after thyroidectomy. Some side effects of drugs were also significantly reduced in combination group.

Download Full-text

Chemotherapy in conjunction with traditional Chinese medicine for survival of patients with early female breast cancer: protocol for a non-randomized, single center prospective cohort study

Trials ◽

10.1186/s13063-019-3848-8 ◽

2019 ◽

Vol 20 (1) ◽

Cited By ~ 4

Author(s):

Chien-Ting Liu ◽

Yen-Hao Chen ◽

Yu-Chuen Huang ◽

Shih-Yu Chen ◽

Ming-Yen Tsai

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Chinese Medicine ◽

Side Effects ◽

Adjuvant Chemotherapy ◽

Traditional Chinese Medicine ◽

Early Breast Cancer ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Single Center

Abstract Background Chemotherapy after surgery for breast cancer plays a fundamental role in reducing the risk of distant and local recurrence. An increasing number of patients seek traditional Chinese medicine (TCM) during adjuvant chemotherapy to relieve symptom discomfort and side effects as well as to strengthen the body’s defenses. However, evidence on how concurrent TCM treatment affects prognosis is scarce. This trial aims to evaluate the association between TCM treatment and disease-free survival outcomes for patients with early breast cancer who are undergoing adjuvant chemotherapy. Methods/design This is a non-randomized, single center, prospective cohort study begun in November 2018 in Kaohsiung, Taiwan. A sample of 310 participants diagnosed with early breast cancer was recruited from the Breast Cancer Research Team and will be followed up every 3 to 6 months until October 2023. Detailed information of the participants, including general information, history of cancer, quality of life, side effects and safety of treatment, TCM body constitution, and meridian energy analysis, was collected face to face at baseline. Discussion This is the first prospective observational cohort study on TCM in patients with early breast cancer who are receiving adjuvant chemotherapy to evaluate the prognosis. Through this trial, we hope to assess the feasibility of a larger-scale clinical trial in the future and formulate an integrated TCM care program. Trial registration ClinicalTrials.gov, NCT03797248. Registered on 5 January 2019.

Download Full-text